

1 **TITLE PAGE**

2

3 **Excess weight increases the risk for neurological and neuropsychiatric symptoms in**
4 **post-COVID-19 condition: A systematic review and meta-analysis**

5 **Short title: Excess weight increases Post-COVID-19 Condition neuro-symptoms**

6

7 Débora Barbosa Ronca^{1,2¶*,#a}, Larissa Otaviano Mesquita^{1,&}, Dryelle Oliveira³, Ana
8 Cláudia Morais Godoy Figueiredo^{2,4,&}, Jun Wen⁵, Manshu Song⁶, Kênia Mara Baiocchi
9 de Carvalho^{1,3¶}

10 ¹ Graduate Program of Public Health, Faculty of Health Sciences, University of Brasília;
11 Brasília, Federal District, Brazil.

12 ² Health Department of Federal District, Brasília, Federal District, Brazil.

13 ³ Graduate Program of Human Nutrition, Faculty of Health Sciences, University of
14 Brasília, Brasília, Federal District, Brazil.

15 ⁴ Superior School of Health Sciences, Brasília, Federal District, Brazil.

16 ⁵ Faculty of Hospitality and Tourism Management, Macau University of Science and
17 Technology, Macau SAR, China.

18 ⁶ School of Medical and Health Sciences, Edith Cowan University, Perth, Western
19 Australia, Australia.

20 ^{#a}Current address: School of Medical and Health Sciences, Edith Cowan University, Perth,
21 Western Australia, Australia.

22

23 **Corresponding authors:** Débora Barbosa Ronca. E-mail: d.ronca@ecu.edu.au /
24 deboraronca@gmail.com (DBR)

25 **Co-corresponding authors:** Kênia Mara Baiocchi de Carvalho. E-mail: kenia@unb.br
26 (KMBC); Manshu Song. E-mail: m.song@ecu.edu.au (MS)

27

28 **Abstract**

29 **Background/purpose:** Excess weight has been identified as a potential risk factor for the
30 development of post-COVID-19 condition (PCC). This review investigates whether
31 excess weight increases the risk of neurological and neuropsychiatric symptoms
32 associated with PCC. **Methods:** Studies published up to July 2023 were searched
33 independently across eight electronic databases to evaluate the risk of developing
34 neurological and neuropsychiatric symptoms more than 12 weeks post-infection between
35 exposure and controls groups (excess weight *vs.* normal weight; obesity *vs.* non-obesity).
36 Meta-analyses were conducted under a random-effects model. **Results:** Of the 10,122
37 abstracts screened, 18 studies ($n = 139,091$ adults) met the inclusion criteria and reported
38 PCC symptoms according to nutritional status. These studies included 79,050 individuals
39 with excess weight *vs.* 57,926 normal-weight individuals and 30,694 individuals with
40 obesity *vs.* 107,612 non-obese individuals. The presence of excess weight in PCC
41 significantly increased the risk of depression (RR = 1.21; 95% CI: 1.03–1.42), headache
42 (RR = 1.21; 95% CI: 1.09–1.35), memory issues (RR = 1.43; 95% CI: 1.24–1.65), sleep
43 disturbance (RR = 1.31; 95% CI: 1.16–1.48), and vertigo (RR = 1.21; 95% CI: 1.04–
44 1.41). Obesity significantly increased the risk of headache (RR = 1.41; 95% CI: 1.34–
45 1.49), smell disorder (RR = 1.15; 95% CI: 1.09–1.21), taste disorder (RR = 1.21; 95% CI:
46 1.07–1.36), and vertigo (RR = 1.44; 95% CI: 1.35–1.53). **Conclusions:** Excess weight or
47 obesity increases the risk of experiencing neuro-symptoms related to PCC. Individuals
48 with these conditions urgently need enhanced personalized care management in current
49 post-pandemic context.

50 **Keywords:** Post-COVID-19 condition, Neurological symptoms, Neuropsychiatric
51 symptoms, Obesity, Systematic review

52

54 **Introduction**

55 A growing body of evidence suggests that a subset of COVID-19 survivors
56 develop persistent, debilitating symptoms and may face a long road to complete
57 recovery[1–4]. These symptoms have been shown to affect multiple organ systems, as
58 evidenced by respiratory, cardiovascular, neurological, and mental health manifestations.
59 This emergent condition has several names: long-COVID; post-acute sequelae of SARS-
60 CoV-2 syndrome; and, as per the World Health Organization (WHO), post-COVID-19
61 condition (PCC). Although PCC has no uniform definition in the literature, it is generally
62 described as involving persistent symptoms or new symptom onset, typically 12 weeks
63 from the acute phase of COVID-19[5, 6], presenting a novel challenge to healthcare
64 systems[7].

65 To date, no comprehensive effective treatment has been recognized for PCC, and
66 the common strategies are based on symptoms relief[8]. Among PCC’s range of
67 symptoms, long-term COVID-19 neurological and neuropsychiatric manifestations are of
68 particular interest given the higher incidence of nervous system related sequelae’s after
69 post-viral epidemics[9]. Prior reviews revealed that smell and taste disorders, headache,
70 sleep disturbance, anxiety and depression were among the most commonly reported
71 persistent symptoms in the general population. However, these studies only follow
72 participants for a few weeks post-COVID infection and do not meet the criteria for
73 PCC[10–13]. The severity of the COVID-19 acute phase has been associated with the
74 development of long-term COVID-19 neuropsychiatric symptoms[14]. The body mass
75 index (BMI) has been regarded as a potential risk factor for PCC, although the association
76 of excess weight (EW) with the development of specific neurological and
77 neuropsychiatric symptoms remains unclear[15, 16]. Moreover, studies that reported the
78 prevalence of persistent neurological and neuropsychiatric symptoms up to one year after

79 COVID-19 onset exhibited considerable heterogeneity and did not perform subgroups
80 analyses according to nutritional status[2, 17]. An increased number of PCC symptoms
81 that longer persist may be experienced by individuals with EW and might be associated
82 to worsen health and poor quality of life[18].

83 It is noteworthy that EW is a chronic suboptimal health condition characterized by
84 excessive fat deposits and is considered a global public health problem. It represents a
85 major risk factor for other chronic conditions and encompasses overweight, a suboptimal
86 body weight that represents a risk to health, and obesity, a metabolic disease[19, 20]. A
87 complex yet costly care of individuals with EW is required, with appropriate
88 multidisciplinary, long-term support[19]. In 2020, the overweight and obesity pandemic
89 collided with the COVID-19 pandemic. These conditions' joint negative effects have
90 increased the incidence of related diseases, leading to potentially adverse clinical and
91 social consequences[21–23]. Obesity was found to be associated with poor COVID-19
92 outcomes, such as hospital admissions, intensive care admissions, and lethality rates[24–
93 26]. Although the COVID-19 pandemic has come under control, the multisystemic nature
94 of this disease and its long-term impacts have yet to be elucidated[10, 27].

95 Although there is literature on the most commonly reported neurological and
96 neuropsychiatric symptoms of PCC, few studies reported the risk of PCC symptoms
97 according to nutritional status and no previous review has explored the association of EW
98 and the risk of developing specific neurological or neuropsychiatric symptoms among
99 COVID-19 survivors. Elucidating the long-term neuro-outcomes of COVID-19, along
100 with its suite of symptoms and high-risk populations, is urgently needed to facilitate the
101 development of reliable and personalized care management strategies. Therefore, this
102 systematic review addresses whether EW increases the risk of developing specific
103 persistent neurological or neuropsychiatric symptoms among COVID-19 survivors.

104 **Materials and Methods**

105 This study followed the Preferred Reporting Items for Systematic Reviews and
106 Meta-Analyses (PRISMA) 2020 guidelines[28]. It is a subset of broad research aimed at
107 investigating the role of EW in the development of persistent symptoms of PCC. This
108 review was registered at the International Prospective Register of Systematic Reviews
109 (PROSPERO) (ID: CRD42023433234).

110 **Search strategy and Eligibility Criteria**

111 Two authors (DBR and LOM) searched seven electronic databases (MEDLINE,
112 EMBASE, SCOPUS, Web of Science, VHL, Google Scholar, ProQuest) and a preprint
113 server (medRxiv) on 3 July 2023. The search strategy was reviewed by two reviewers
114 according to the criteria of the Peer Review of Electronic Search Strategies (PRESS)
115 checklist[29]. The search strategy included the following terms: (“long COVID-19” OR
116 “post-acute covid 19 syndrome” OR “COVID-19” OR “SARS-CoV-2” OR “post-
117 COVID-19 condition” OR “long hauler”) AND (“excess of weight” OR “overweight”
118 OR “obesity” OR “body mass index”) AND (“signs and symptoms” OR “COVID-19
119 sequelae” OR “headache” OR “loss of smell” OR “cognitive dysfunction” OR “anxiety”
120 OR “depression” OR “sleep disorder” OR “brain fog.” The full search strategy is detailed
121 in supporting information (S1 Table). Additionally, some articles were hand-searched to
122 identify potentially eligible studies which might not be electronically retrieved, including
123 those published in 2024.

124 Studies were considered eligible for inclusion if they (a) had observational
125 designs; (b) primarily focused on adults; (c) classified focal populations based on the
126 presence of excess weight/obesity *versus* normal weight/non-obesity, using either
127 measured BMI or self-reported data; and (d) had a mean (or median) follow-up of at least
128 12 weeks after the acute phase of COVID-19. Survivors could be (a) hospitalized or non-

129 hospitalized, (b) inpatient or outpatient, and (c) mixed population (hospitalized and
130 outpatient) recruited in the community, outpatient clinic or health care system.

131 We exclude editorials, clinical trials, reviews, opinions, books or book chapters,
132 conference abstracts, case reports, and correspondence articles. Studies were also
133 excluded if they included mostly pregnant or nursing women; evaluated the health effects
134 of COVID-19; assessed excess weight as a risk factor for acute-phase severity or
135 mortality; or evaluated long-term sequelae of COVID-19 in a specific population (e.g.,
136 individuals with specific comorbidities). Additionally, studies were excluded if they
137 investigated clusters of symptoms rather than specific symptoms or if they lacked a
138 control group (i.e., COVID-19 survivors who did not report persistent symptoms).

139 **Screening Process, Study Selection, and Data Extraction**

140 The same two authors (DBR and LOM) independently screened the titles and
141 abstracts of studies obtained from database searches and removed duplicates. The Rayyan
142 app[30], a semi-automation tool, was used to streamline the review process. This was
143 followed by a full-text review of the retained articles to ensure they met eligibility criteria.

144 Fig 1 presents the flowchart for the included studies.

145

146 **Fig 1: Flow diagram of included studies.**

147

148 The study population of interest comprised COVID-19 survivors. Exposure was
149 defined as EW or obesity based on BMI measurement, data from electronic medical
150 records, or self-reported information. Two exposure groups were defined according to
151 WHO guidelines[31]: 1) an excess weight group ($BMI \geq 25 \text{ kg/m}^2$) and 2) an obesity
152 group ($BMI \geq 30 \text{ kg/m}^2$). Both Asian and Caucasian populations were included in the
153 analysis, with corresponding BMI cut-offs applied: for Asian-Pacific populations, the

154 thresholds were BMI ≥ 23 kg/m² for EW and BMI ≥ 25 kg/m² for obesity, as previously
155 defined in the included studies[32, 33].

156 We adopted WHO's definition of PCC as outlined by Soriano *et al.* (2021)[5].
157 Symptoms were measured with predefined questionnaires/scales or reported during
158 interviews (in person, by phone, or online). Due to varying definitions illness onset
159 (baseline), we accepted definitions that included 12 weeks from the onset of COVID-19
160 symptoms, COVID-19 diagnosis, hospital admission or discharge after the acute phase.
161 For the follow-up period, we considered studies where the sample median (or mean) of
162 persistent symptoms was reported at least 12 weeks (84 days) after the baseline, with a
163 minimum interquartile range (IQR) of 10 weeks (or a standard deviation (SD) of ± 24
164 days) from baseline. This cut-off was necessary to include studies evaluating long-term
165 sequelae of COVID-19. Given the varied terminology used for symptoms across studies,
166 we re-grouped symptoms into neurological and neuropsychiatric categories as shown in
167 Fig 2.

168

169 **Fig 2: Reported neurological and neuropsychiatric symptoms related to Post-**
170 **COVID-19 condition (PCC).** ^aNeurological and neuropsychiatric reported symptoms were grouped
171 into one category with synonyms presented in brackets.

172

173 Specific data were exported from each study into a predefined data collection
174 form, including authors; publication year; country; aim of the study; study design; mean
175 follow-up period; study population; exposure groups; assessment of outcome; evaluated
176 symptoms; frequency of symptoms (*n*, %) among exposure and control groups; and the
177 effect measure of the association of EW and the neurological/neuropsychiatric symptom.
178 Corresponding authors of relevant articles published were contacted if any data were
179 absent.

180 **Quality Assessment**

181 The ROBINS-E tool for observational research was used to determine the risk of
182 bias in the included studies[34]. ROBINS-E is a domain-based tool that evaluates seven
183 domains (confounders, exposure measurement, participant selection, post-exposure
184 interventions, missing data, outcome measurement, and selection of reported results) and
185 then a general assessment of the study. Traffic plots with a final analysis of studies' risk
186 of bias, by domain, is generated. For this research, two authors (DBR and DO) initially
187 appraised the risk of bias. Disagreements were discussed and resolved in collaboration
188 with a third researcher (LOM). The ROBINS-E tool was not applied as a study eligibility
189 criterion.

190 We assessed the certainty of evidence via the Grading of Recommendations
191 Assessment, Development and Evaluation (GRADE) framework [35–37] regarding the
192 risk of developing PCC-related neurological and neuropsychiatric symptoms among
193 individuals with EW. The GRADE system measures attributes that impact the overall
194 quality of evidence. We assessed the certainty of evidence of the outcomes that were
195 statistically significantly associated with exposures groups and scored it accordingly (i.e.,
196 high = ≥ 4 points; moderate = 3 points; low = 2 points; very low = 1 point).

197 **Statistical Analysis**

198 The frequency of reported symptoms and the associated risk of development were
199 determined for EW *vs* normal weight groups and for obesity *vs* non-obesity groups,
200 classified by BMI when available (normal weight: BMI of 18–24.9 kg/m²; excess weight:
201 BMI >25 kg/m²; obesity: BMI >30 kg/m²; non-obesity group: BMI <30 kg/m²), taking
202 into account different cut-off values previously defined for the Chinese population in
203 studies[32, 33]. Each symptom was considered an individual outcome. For this purpose,
204 we collected data of the frequency (*n*, %) of each neurological and neuropsychiatric

205 symptoms related to PCC reported and the risk of developing persistent symptoms (as
206 measured by the odds ratio [OR] or the adjusted OR) at follow-up in included studies.

207 We performed meta-analytic calculations using STATA software (SE/17). Pooled
208 risk ratios (RRs) with their 95% confidence intervals (CIs) were computed from the raw
209 data of the included studies. A random effects model meta-analysis was conducted to
210 account for the statistical and methodological heterogeneity of the data. We used a two-
211 sample binary-outcome summary dataset format with DerSimonian–Laird estimation
212 when fewer than five studies were available[38]; when more than five studies were
213 available, we adopted restricted maximum-likelihood estimation and to conduct pooled
214 RR analysis. Statistical heterogeneity was assessed using the I^2 statistic[39]. Forest plots
215 were generated for all outcomes. Publication bias was examined by visual inspection of
216 funnel plots. A value of $p < 0.05$ was considered statistically significant.

217

218 **Results**

219 Of the 10,122 abstracts screened, 211 full-text registers were reviewed, and 65
220 studies were considered eligible. Data on neurological and neuropsychiatric symptoms
221 according to individuals' nutritional status were available for 18 studies (including one
222 preprint[40]), all of which were entered into our meta-analysis.

223 Selected studies originated from 23 countries across Asia (China[32, 33],
224 India[41], Indonesia[42], Japan[43], Malaysia[40] and Saudi Arabia[44]), Europe
225 (Denmark[45, 46], England[47], Germany[48], Italy[49], Poland[50], Spain[51] and
226 Switzerland[52]), and North and South America (Argentina[53], Brazil[53], Chile[53],
227 Dominican Republic[53], Ecuador[53], Mexico[53], Panama[53], Paraguay[53],
228 Peru[53] and United States of America[54, 55]), comprising both developed and
229 developing countries. Among the included studies, two employed case–control design[51,

230 54], six involved retrospective or prospective cohorts[33, 42, 49, 50, 52, 55], and 10
231 involved cross-sectional studies[32, 40, 41, 44–47, 47, 48, 53].

232 The populations investigated varied: three studies evaluated individuals in
233 outpatient settings[46, 52, 54], five involved hospitalized patients[32, 33, 42, 49, 51] ,
234 and ten included individuals either hospitalized or outpatient settings during COVID-19
235 acute-phase[40, 41, 43, 44, 47, 48, 50, 53, 55]. The classification of individuals according
236 to nutritional status also varied: four studies compared symptoms between individuals
237 with EW and those with normal weight[32, 40, 42, 44], five studies evaluated obesity
238 *versus* non-obesity[33, 48–51], eight studies presented data for individuals with normal
239 weight, overweight and obesity[41, 45–47, 52–55], and one study only provided the mean
240 BMI of the sample without specifying the number of individuals in exposure and control
241 groups[43]. In total, our meta-analysis included 79,050 people with EW and 30,694 with
242 obesity in exposure groups, while 57,926 normal weight individuals and 107,612 non-
243 obese individuals comprised control groups. Sample sizes ranged from 32[54] to
244 78,566[47] COVID-19 survivors. Two Chinese studies applied different cut-off points for
245 nutritional status classification (EW as BMI ≥ 23 kg/m²; obesity as BMI ≥ 25 kg/m²)[32,
246 33]. Exposure was assessed via anthropometric measures[32, 33, 41, 50, 53, 54],
247 electronic medical record data[42, 46, 49, 51], and self-reported comorbidity/BMI[40,
248 43–45, 47, 52, 55]. PCC neurological and neuropsychiatric symptoms were evaluated
249 using questionnaires[33, 41, 43–47, 50–52, 54], validated scales[32, 40, 48, 49, 51, 54],
250 or self-report instruments[42, 47, 48, 53, 55]. The mean time from COVID-19 onset
251 (baseline) to long-term symptom assessment was 25.8 weeks (range: 12 weeks[42, 44,
252 46, 47, 49] to 52 weeks [one year][32]). Table 1 outlines the features of the included
253 articles.

254

Table 1. Characteristics of included studies.

Author, Year	Country	Study aim	Study design; Follow-up^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
Alkwai, H.M. <i>et al.</i> , 2022 [44]	Saudi Arabia	To analyze the persistence of COVID-19 symptoms and return to the usual state of health	Cross-sectional; 12 weeks after COVID-19 infection	Mixed population ^b <i>n</i> = 108 (male = 23) Age range: 18–65 years	Overweight (<i>n</i> = 32) Normal weight (<i>n</i> = 181)	Online survey Self-reported comorbidities Symptom questionnaire	N: Concentration issues, headache, memory issues, numbness, smell disorder, taste disorder, vertigo NP: mood change, sleep disturbance
Blümel, J.E. <i>et al.</i> , 2022 [53]	Nine Latin-American countries ^c	To study the development of long-term symptoms and the impacts of COVID-19 on mental health and quality of life in middle-aged women	Cross-sectional; 32 weeks after COVID-19 infection	Mixed population ^b Sample of interest / study sample <i>n</i> = 304/1,238 (female only) Age: 53.0 (range: 40–64 years)	Obesity (<i>n</i> = 41) Overweight (<i>n</i> = 124) Normal weight (<i>n</i> = 139)	In-person interview Measured BMI Reported symptoms	N: anorexia, cognitive deficit, headache, memory issues, numbness, smell disorder, taste disorder, vertigo NP: anxiety, sleep disturbance
Bungenberg, J. <i>et al.</i> , 2022 [48]	Germany	To identify and compare persistent self-reported symptoms in initially hospitalized and non-hospitalized patients after infection	Cross-sectional; 13.4 weeks for non-hosp. and 41 weeks for hosp. patients after acute symptoms	Mixed population ^b <i>n</i> = 50 (male = 22) Age: 50.5 (range: 40–64 years)	Obesity (<i>n</i> = 7) Non-obesity (<i>n</i> = 43)	In-person interview Reported symptoms and scales	N: cognitive deficit, memory issues, smell disorder, taste disorder, vertigo NP: sleep disturbance

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
Carter, S.J. <i>et al.</i> , 2022 [54]	United States of America	To compare functional status, mood state, and physical activity in leisure time among positive COVID-19 and controls	Case-control; 12.1 weeks after COVID-19 diagnosis	Outpatient <i>n</i> = 32 woman SARS-CoV-2 group = 17 Age: 55 ± 11 years	Obesity (<i>n</i> = 4) Overweight (<i>n</i> = 6) Normal weight (<i>n</i> = 7)	In-person interview Measured BMI Questionnaire and Profile of Mood States	N: Cognitive deficit, headache, memory issues, smell disorder, taste disorder
Chudzik, M. <i>et al.</i> , 2022 [50]	Poland	To analyse the prevalence of self-reported smell and/or taste disorders and to identify risk factors for the disease	Cohort; 28.8 weeks starting 14 days after last COVID-19 symptom	Mixed population ^b <i>n</i> = 2,218 (male = 1,410) Age: 53.8 ± 13.5 years	Obesity (<i>n</i> = 692) Non-obesity (<i>n</i> = 1,485)	In-person interview Measured BMI Health questionnaire	N: Smell and taste disorders
Desgranges, F. <i>et al.</i> , 2022 [52]	Switzerland	To compare the prevalence of symptoms persisting for more than 3 months and to identify predictors of persistent symptoms	Cohort; 21.4 weeks after initial consultation (IQR: 17.2–29.1)	Outpatient Sample of interest / study sample <i>n</i> = 418/507 (male = 157) Age: 41 (range: 31–54 years)	Obesity (<i>n</i> = 72) Overweight/obesity (<i>n</i> = 189) Healthy weight (<i>n</i> = 229)	Electronic medical records Telephone interviews Self-reported BMI Survey with predefined symptoms	N: Headache, loss of balance, memory issues, numbness, smell disorder, taste disorder NP: sleep disturbance
Epsi, N.J. <i>et al.</i> , 2024 [55]	United States of America	To improve the definition of PCC with a data-driven approach to phenotyping.	Cohort 24 weeks post-infection	Mixed population ^b <i>n</i> = 1,988 (male = 1,201)	Obesity (<i>n</i> = 710) Overweight (<i>n</i> = 842) Normal weight (<i>n</i> = 436)	Electronic patient records and self-reported BMI Online survey	N: Smell and taste disorder

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
				Age: 69,5% were between 18-44 years old		Survey with predefined symptoms	
Farhanah, N. <i>et al.</i> , 2022 [42]	Indonesia	To determine persistent symptoms and evaluate quality of life in COVID-19 patients 3 months after discharge	Cohort; 12 weeks after hospital discharge	Hospitalized <i>n</i> = 104 (male = 55) Age: 48.9 (range: 18–65 years)	Excess weight (<i>n</i> = 41) Normal weight (<i>n</i> = 63)	Electronic medical records Telephone interviews Reported symptoms	N: headache, smell disorder, sweating, taste disorder NP: sleep disturbance
Fernández-de- Las-Peñas, C. <i>et al.</i> , 2021 [51]	Spain	To investigate the association of obesity with long-term post-COVID symptoms in hospitalized COVID-19 survivors	Case-control; 28.8 weeks after hospital discharge	Hospitalized <i>n</i> = 264 (male = 159) Age: 52.0 ± 14.5 years	Obesity (<i>n</i> = 88) Non-obesity (<i>n</i> = 176)	Electronic medical records Telephone interviews List of symptoms Hospital Anxiety and Depression Scale, Pittsburgh Sleep Quality Index (PSQI)	N: Concentration issues, cognitive deficit, headache, memory issues, numbness, sleep disturbance, smell and taste disorders NP: anxiety, depression
Gaur, R. <i>et al.</i> , 2022 [41]	India	To assess the extent of disability following COVID-19 infection	Cross-sectional; 15.5 weeks after COVID-19 infection	Mixed population ^b <i>n</i> = 97 (male = 61) Age: 48.7 ± 15.6 years	Obesity (<i>n</i> = 32) Overweight (<i>n</i> = 27) Normal weight (<i>n</i> = 38)	In-person interview Measured BMI Questionnaire	N: Headache, vertigo NP: Sleep disturbance
Li, Z. <i>et al.</i> , 2023 ^d [32]	China	To investigate the mental health status of COVID-19	Cross-sectional;	Hospitalized <i>n</i> = 535 (male = 216)		Self-reported survey Measured BMI	N: Anxiety, depression NP: Sleep disturbance

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
		survivors 1 year after discharge and reveal related risk factors	52 weeks (12 months) after hospital discharge	Age: 50.8 ±14.4 years	BMI ≥23 (<i>n</i> = 221) BMI 18.5–22.9 (<i>n</i> = 295)	Questionnaire, General Anxiety Disorder-7 scale, Patient Health Questionnaire (PHQ)-9, PSQI	
Miyazato, Y. <i>et al.</i> , 2022 [43]	Japan	To explore the factors involved in PCC development in a cohort of patients recovering from COVID-19 at a hospital in Japan	Cross-sectional; 35.5 weeks after symptom onset or COVID-19 diagnosis	Mixed population ^b ; <i>n</i> = 457 (male = 226) Age: 47 (IQR: 39–55 years)	BMI as continuous variable	Online survey Self-reported BMI Questionnaire with list of symptoms	N: Smell and taste disorders
Moy, F.M. <i>et al.</i> , 2022 [40]	Malaysia	To investigate mental health status in the form of depression among COVID-19 survivors and its associated factors	Cross-sectional; 27.3 weeks after COVID-19 infection	Mixed population ^b Sample of interest / study sample <i>n</i> = 567/732 (male = 302) Age: 40.2 ± 10.9 years	Overweight/obese (<i>n</i> = 315) Normal weight /underweight (<i>n</i> = 246)	Online survey Reported BMI PHQ-9	NP: Depression
Shang, L. <i>et al.</i> , 2021 ^d [33]	China	To determine whether obesity has a long-term impact on COVID-19 recovery	Cohort; 46.1 weeks after hospital discharge	Hospitalized <i>n</i> = 118 (male = 48) Age: 53.0 (IQR: 44–61 years)	Obesity (<i>n</i> = 53) Non-obesity (<i>n</i> = 65)	In-person interview Measured BMI Questionnaire	N: Smell disorder NP: sleep disturbance

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
Sørensen, A.I.V., <i>et al.</i> , 2022 [45]	Denmark	To estimate the risk difference between COVID-19 positive and negative individuals; to evaluate the duration of symptoms; to explore the influence of risk factors on persistent symptoms	Cross-sectional; 38 weeks after COVID-19 test.	Mixed population ^b (96% of outpatient) Sample of interest / study sample $n = 61,002/152,880$ (male = 25,172) Age: 49.0 (IQR: 39–60 years)	Obese ($n = 9,950$) Overweight ($n = 19,264$) Normal weight ($n = 25,285$)	Online survey and electronic records Self-reported BMI Web-based questionnaire	N: Headache, smell disorder, taste disorder, vertigo
Van-Wijhe, M. <i>et al.</i> , 2022 [46]	Denmark	To investigate the occurrence and risk factors for long-COVID symptoms and health-related quality of life	Cross-sectional; 12 weeks after positive PCR test	Outpatient Sample of interest / study sample $n = 742/7420$ (male = 245) Age: 48.2 ± 15.0	Obesity ($n = 148$) Overweight ($n = 226$) Normal weight ($n = 368$)	Electronic patient records and online survey Questionnaire	N: Concentration issues, headache, memory issues, smell disorder, taste disorder, vertigo
Vassalini, P. <i>et al.</i> , 2021 [49]	Italy	To assess the prevalence of depressive symptoms and related risk factors at 3 months after hospitalization for COVID-19 infection	Cohort 12 weeks after hospital discharge	Hospitalized $n = 115$ (male = 62) Age: 47 (IQR: 48–66 years)	Obesity ($n = 5$) Non-obesity ($n = 110$)	Electronic medical records and telephone interviews PHQ-9	NP: Depression
Whitaker, M. <i>et al.</i> , 2022 [47]	England	To estimate symptom prevalence; to investigate co-	Cross-sectional;	Mixed population ^b Sample of interest / study sample	Obesity ($n = 18,892$) Overweight ($n = 27,986$)	Survey (online/telephone) Self-reported BMI	N: Headache, memory issues, numbness, smell disorder, taste disorder, vertigo

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
		occurrence of symptoms and assess risk factors for persistence of symptoms	12 weeks after symptom onset	<i>n</i> = 78,566/606,434 (male = 37,600) Age: 80% of sample between 25 and 65 years old	Normal weight (<i>n</i> = 30,639)	Questionnaire and self-reported symptoms	NP: sleep disturbance

256 BMI: body mass index; PCR: polymerase chain reaction; IQR: interquartile range.

257 ^a Mean or median of follow-up time, in weeks;

258 ^b Hospitalized and outpatient;

259 ^c Argentina, Brazil, Chile, Dominican Republic, Ecuador, Mexico, Panama, Paraguay, and Peru;

260 ^d Different cut-off values were used to define excess weight and obesity in Asian populations.

261

262

263

264

265

266

267

268 Half of the studies[32, 33, 40, 43, 46, 50–52, 55] tested for differences in the
269 prevalence or risk of developing PCC neurological and neuropsychiatric symptoms based
270 on to nutritional status. One study found that BMI was inversely associated with the risk
271 of developing smell and taste disorders[43]. Positive associations between EW and
272 anxiety[32], depression[32, 40], and sleep disturbance[51, 52] were also reported, with
273 obesity being independently associated with sleep disturbance[51]. Table 2 displays data
274 on the frequency and risk of developing neurological and neuropsychiatric symptoms of
275 PCC from studies that examined differences between exposure and control groups. Other
276 studies[41, 42, 44, 45, 47–49, 53, 54] did not test for differences in the prevalence or risk
277 of specific persistent neuropsychiatric symptoms. Data on symptom frequency by
278 nutritional status are available in the supporting information (S2 Table).

279

280

281

282

283

284

285

286

287

288

289

290

291

292

Table 2. Frequency of neuropsychiatric symptoms related to post-COVID condition and the risk of their development in included studies.

Author, year	Frequency (%) of PCC Symptoms according to nutritional status		Significantly higher frequency of symptoms among exposure groups? (Yes / No)	Effect measure of nutritional status on the risk/protection of developing a PCC symptom aOR (95%CI)	Exposure increased the risk of symptoms? (Yes / No)	
	Excess Weight versus Exposure groups	Normal Weight Control group				
Desgranges, F. <i>et al.</i> , 2022	Smell and taste disorders			1.01 (0.61-1.67); $p=0.96$	No	
	Headache			0.79 (0.48-1.75); $p=0.79$	No	
	Loss of balance	NA	NA	NA	1.46 (0.35-6.09); $p=0.61$	No
	Memory issues				1.79 (0.93-3.44); $p=0.08$	No
	Numbness				2.74 (0.79-9.50); $p=0.11$	No
	Sleep disturbance				2.08 (1.03-4.21); $p=0.04^*$	Yes
Epsi, N.J. <i>et al.</i> , 2024	Smell and taste disorder	0.01	0.02	No	0.89 (0.37–2.12)	No
Li, Z. <i>et al.</i> , 2023 ^a	Anxiety	16.3	13.8; $p=0.000^*$	Yes	NA	NA
	Depression	21.7	19.0; $p=0.052^*$	No		
	Sleep disturbance	51.1	43.3; $p=0.018^*$	Yes		
Miyazato, Y. <i>et al.</i> , 2022	Smell disorder	NA	NA	NA	0.94 (0.89-0.99); $p=0.014^*$	Yes
	Taste disorder				0.93 (0.88-0.98); $p=0.012^*$	Yes
Moy, F.M. <i>et al.</i> , 2022	Depression	51.7	42.3; $p=0.026^*$	Yes	1.83 (1.18-2.82)	Yes
Van-Wijhe, M. <i>et al.</i> , 2022	Concentration issues				1.01 (0.70-1.47)	No
	Headache				1.09 (0.75-1.58)	No
	Memory impairment				0.94 (0.62-1.42)	No
	Taste disorder	NA	NA	NA	0.85 (0.61-1.32)	No
	Smell disorder				0.72 (0.45-1.05)	No
	Vertigo				0.95 (0.64-1.42)	No

	Obesity versus Non-obesity		(Yes / No)	OR (95%CI)	(Yes / No)	
	Exposure groups	Control group				
Chudzik, M. <i>et al.</i> , 2022	Smell and taste disorder	3.1	5.1	No	0.65 (0.35-1.22); <i>p</i> =0.185	No
Epsi, N.J. <i>et al.</i> , 2024	Smell and taste disorder	0.01	0.02	No	0.76 (.29–1.99)	No
Fernández-de-las-Peñas, C. <i>et al.</i> , 2021	Ageusia	8.0	6.8	Yes	NA	NA
	Anosmia	2.3	6.8	No	NA	NA
	Anxiety	15.9	9.7	Yes	1.75 (0.82-3.72); <i>p</i> = 0.146	No
	Cognitive deficit	9.1	6.8	Yes	NA	NA
	Concentration issues	13.6	9.1	Yes	NA	NA
	Depression	13.6	15.9	No	0.83 (0.40-1.73); <i>p</i> = 0.628	No
	Headache	8.0	5.7	Yes	NA	NA
	Memory impairment	18.2	14.8	Yes	NA	NA
	Sleep disturbance	45.5	25.6	Yes	2.10 (1.13-3.83); <i>p</i> =0.020*	Yes
Shang, L. <i>et al.</i> , 2021 ^a	Sleep disturbance	39.6	44.6; <i>p</i> = 0.590	No	NA	NA
	Smell disorder	7.5	7.7; <i>p</i> = 0.970	No		
Van-Wijhe, M. <i>et al.</i> , 2022	Concentration issues				0.96 (0.62-1.49)	No
	Headache				1.06 (0.69-1.65)	No
	Memory impairment				0.92 (0.56-1.50)	No
	Taste disorder	NA	NA	NA	1.00 (0.65-1.55)	No
	Smell disorder				0.83 (0.53-1.55)	No
	Vertigo				0.90 (0.56-1.45)	No

*Statistically significant; NA: non-available information; excess-weight group (BMI ≥ 25 kg/m²); normal-weight group (BMI < 25 kg/m²); obesity group (BMI ≥ 30 kg/m²); non-obesity group (BMI < 30 kg/m²). ^a Different cut-off values were used to define excess weight and obesity in Asian populations (excess weight ≥ 23 kg/m²; obesity ≥ 25 kg/m²).

293 **Excess Weight and the Risk of Neuropsychiatric Symptoms**

294 We assessed the risk ratios (RRs) for the EW group (Figs 3a and 3b). Excess
295 weight significantly increased the risk of depression (RR = 1.21; 95% CI: 1.03–1.42; $I^2 =$
296 0.00), headache (RR = 1.21; 95% CI: 1.09–1.35; $I^2 = 41.3\%$), memory issues (RR = 1.43;
297 95% CI: 1.24–1.65; $I^2 = 0.00$), numbness (RR = 1.37; 95% CI: 1.24–1.51; $I^2 = 0.00$), sleep
298 disturbance (RR = 1.31; 95% CI: 1.16–1.48; $I^2 = 17.83$), taste disorder (RR = 1.11; 95%
299 CI: 1.00–1.23; $I^2 = 53.46$), and vertigo (RR = 1.21; 95% CI: 1.04–1.41; $I^2 = 0.00$). No
300 significant association was found between EW and other evaluated symptoms (S1 Figs
301 1a and 1b).

302

303 **Fig 3a. Forest plots of excess weight and risk ratio (RR) for neurological and**
304 **neuropsychiatric symptoms.** ^a Applied a different cut-off of BMI. Excess weight > 23kg/m².

305 **Fig 3b; Forest plots of excess weight and risk ratio (RR) for neurological and**
306 **neuropsychiatric symptoms (Continuation).**

307

308 Four studies employed multivariate logistic regression and reported the risk of
309 developing headache, smell disorder, memory impairment and taste disorder. These data
310 were included in the meta-analysis. Pooled results revealed a significant association
311 indicating that the risk of developing taste disorder was inversely associated with BMI
312 (OR 0.93; 95%CI 0.88-0.98; $I^2=0,00$). No significant associations were found for other
313 evaluated symptoms (S2 Fig 2).

314 **Obesity and the Risk of Neuropsychiatric Symptoms**

315 Our pooled risk analysis for obesity and neurological and neuropsychiatric
316 symptoms (Figs 4a and 4b) showed that individuals with obesity are at significantly

317 higher risk than those with normal weight or overweight (non-obesity control group) for
318 a range of neurological symptoms: headache (RR = 1.41; 95% CI: 1.34–1.49; $I^2 = 3.39$);
319 numbness (RR = 1.61; 95% CI: 1.46–1.78; $I^2 = 0.00$); smell disorder (RR = 1.15; 95%
320 CI: 1.09–1.21; $I^2 = 7.55$); taste disorder (RR = 1.21; 95% CI: 1.07–1.36; $I^2 = 63.57$); and
321 vertigo (RR = 1.44; 95% CI: 1.35–1.53; $I^2 = 0.00$). No statistically significant association
322 was found between obesity and the risk of developing PCC-related neuropsychiatric
323 symptoms (S1 Fig 1b).

324

325 **Fig 4a. Forest plot of obesity and risk ratio (RR) for neurological and**
326 **neuropsychiatric symptoms.** ^a Applied a different BMI cut-off (obesity >25 kg/m²).

327 **Fig 4b. Forest plot of obesity and risk ratio (RR) for neurological and**
328 **neuropsychiatric symptoms (continuation)**

329

330 Substantial heterogeneity was observed in our meta-analysis for the non-
331 significant association of obesity and anxiety ($I^2 = 70.5\%$) and sleep disorder ($I^2 =$
332 61.94%) as well as for the statistically significant association between obesity and taste
333 disorder ($I^2 = 69.5\%$). Meanwhile, no statistically significant heterogeneity was observed
334 in other analyses where obesity was the exposure condition. Subgroup analyses could not
335 be performed due to an insufficient number of studies evaluating the same outcome
336 according to nutritional status.

337 **Risk-of-bias Assessment and Publication Bias**

338 We assessed the risk of bias for each effect measure (frequency and OR). Results
339 for studies reporting the frequency of PCC symptoms are presented in Fig 5; while
340 findings for studies reporting OR are displayed in Supporting Information (S3 Fig 3).
341 Among the 18 studies evaluated, seven were judged to have a high risk of bias due to self-

342 reported exposure data[40, 43–45, 47, 52, 55]. The ROBINS-E tool indicated that no
343 further evaluation of a study was required for studies with inappropriate measurement of
344 exposure or outcome; therefore, this tool was applied only to the remaining 11 studies[32,
345 33, 41, 42, 46, 48–51, 53, 54].

346 **Fig 5: Summary plot and traffic light plot illustrating the risk of bias in the included**
347 **studies, assessed using the ROBINS-E tool.**

348

349 The domain most affecting the assessment was control for confounders (Domain
350 1 [D1]). Few studies employed appropriate designs (e.g., randomization or matching)[46,
351 51, 54] or analytical methods (e.g., stratification)[32, 48–50]; only one study had an
352 overall low risk of bias[50]. Concerns were also noted regarding exposure measurement
353 (Domain 2 [D2]), particularly when data were obtained from electronic medical records
354 without reporting time-related information[51]. Visual assessment of the funnel plots did
355 not imply asymmetry.

356 Findings from the GRADE assessment are presented in Table 3 and supporting
357 information (S3 Table). The quality of evidence was downgraded from high to very low
358 for three outcomes (headache, taste disorder, and vertigo) due to high risk of bias,
359 imprecision of results, and publication bias. For the other outcomes, the quality of
360 evidence was rated as low, having been downgraded from high due to risk of bias and
361 publication bias.

362

363

Table 3. Assessment of the overall certainty of the evidence.

Certainty assessment							No of patients		Effect		Certainty
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Excess weight	normal weight	Relative (95% CI)	Absolute (95% CI)	
Depression (follow-up: range 27 to 52 weeks; assessed with: Scales)											
2	non-randomised studies	serious ^a	not serious	not serious ^a	not serious	publication bias strongly suspected ^b	211/536 (39.4%)	160/541 (29.6%)	RR 1.21 (1.03 to 1.42)	62 more per 1000 (from 9 more to 124 more)	⊕⊕○○ Low ^{a,b}
Sleep disturbance (follow-up: range 12 to 52 weeks; assessed with: Questionnaire and scales)											
6	non-randomised studies	serious ^a	not serious	not serious	not serious	publication bias strongly suspected ^b	3861/47449 (8.1%)	1958/31420 (6.2%)	RR 1.31 (1.16 to 1.48)	19 more per 1000 (from 10 more to 30 more)	⊕⊕○○ Low ^{a,b}
Headache (follow-up: range 12 to 387 weeks; assessed with: Questionnaire and self-reported)											
7	non-randomised studies	serious ^a	not serious	not serious	serious ^c	publication bias strongly suspected ^b	4475/76399 (5.9%)	2773/56352 (4.9%)	RR 1.15 (1.07 to 1.22)	7 more per 1000 (from 3 more to 11 more)	⊕○○○ Very low ^{a,b,c}
Memory issues (follow-up: range 12 to 32 weeks; assessed with: Questionnaire)											
3	non-randomised studies	serious ^a	not serious	not serious	not serious	publication bias strongly suspected ^b	563/7041 (8.0%)	267/4831 (5.5%)	RR 1.43 (1.24 to 1.65)	24 more per 1000 (from 13 more to 36 more)	⊕⊕○○ Low ^{a,b}
Numbness (follow-up: range 12 to 32 weeks; assessed with: Questionnaire)											
3	non-randomised studies	serious ^a	not serious	not serious	not serious	publication bias strongly suspected ^b	1141/47075 (2.4%)	550/30959 (1.8%)	RR 1.37 (1.24 to 1.51)	7 more per 1000 (from 4 more to 9 more)	⊕⊕○○ Low ^{a,b}

Certainty assessment							No of patients		Effect		Certainty
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Excess weight	normal weight	Relative (95% CI)	Absolute (95% CI)	

Taste disorder (follow-up: range 12 to 38 weeks; assessed with: Questionnaire and self-reported)

5	non-randomised studies	serious ^a	not serious	not serious	serious ^{d,e}	publication bias strongly suspected ^b	4914/76 330 (6.4%)	3445/56 307 (6.1%)	RR 1.11 (1.00 to 1.23)	7 more per 1000 (from 0 fewer to 14 more)	⊕○○○ Very low ^{a,b,d}
---	------------------------	----------------------	-------------	-------------	------------------------	--	--------------------------	--------------------------	----------------------------------	---	-----------------------------------

Vertigo (follow-up: range 12 to 38 weeks; assessed with: Questionnaire and self-reported)

5	non-randomised studies	serious ^a	not serious	not serious	serious ^f	publication bias strongly suspected ^b	2795/76 348 (3.7%)	1764/56 282 (3.1%)	RR 1.21 (1.04 to 1.41)	7 more per 1000 (from 1 more to 13 more)	⊕○○○ Very low ^{a,b,c}
---	------------------------	----------------------	-------------	-------------	----------------------	--	--------------------------	--------------------------	----------------------------------	--	-----------------------------------

CI: confidence interval; **RR:** risk ratio; a. The risk of bias of included studies is related to measurement of exposure (self-reported) or confounders control, especially regarding severity of COVID-19 acute phase; b. There are less than 10 studies included in the meta-analysis therefore we were unable to evaluate publication bias; c. Meta-analysis showed moderate heterogeneity among included studies ($I^2 = 41\%$); d. The quality of evidence was downgraded from high due to the high risk of bias of included studies; e. Meta-analysis showed moderate heterogeneity among included studies ($I^2 = 53\%$); f. Meta-analysis showed moderate heterogeneity among included studies ($I^2 = 59.5\%$).

364 **Discussion**

365 Although it has been suggested that individuals with increased BMI are at higher
366 risk of PCC, the associations between EW and specific PCC related neurological and
367 neuropsychiatric symptoms remained unclear. Our review reveals that EW is significantly
368 associated with a range of persistent and PCC symptoms, including headache, vertigo,
369 smell and taste disorder, sleep disturbance and depression. These findings suggest that
370 EW markedly increases the risk of developing these symptoms that persist for more than
371 12 weeks after COVID-19 onset. Moreover, this study is opportune as we transition into
372 the post-pandemic period facing the challenges of managing the co-occurrence of
373 pandemics, including overweight/obesity, mental health issues, and the burden of PCC.

374 Increased BMI has been identified as a determinant of adverse outcomes during
375 both the acute and chronic phases of COVID-19[16, 24, 26]. This contrasts with the role
376 of sex in the disease course since the pattern of acute phase symptoms by sex is distinct
377 from that of PCC, which tends to affect more females[18, 56]. Additionally, the chronic
378 phase of COVID-19's has been variously defined, with some studies indicating symptoms
379 lasting for at least 4 weeks[10] and others extending to more than 12 weeks[5, 6].
380 Differentiating these time frames is crucial to distinguish between acute illness and
381 potential sequelae of irreversible tissue damage, which may present with varying degrees
382 of impairment[57]. In our review, we used the cut-off criterion to ensure that we focused
383 on long-term or chronic outcomes of COVID-19. The mean follow-up time from illness
384 onset in the included studies was 25.8 weeks (ranging from 12 to 52 weeks). A large
385 systematic review[2] evaluated the prevalence of persistent symptoms among COVID-19
386 survivors at different follow-up periods. It identified sleep disorder and concentration
387 difficulties as the most common symptoms at 3–6 months (24%, 95% CI: 8%–44%; 22%,
388 95% CI: 15%–31%, respectively), with sleep disorder being most prevalent at over 12

389 months. However, unlike our results, this review had a high degree of between-study
390 heterogeneity and did not include BMI in subgroups analysis.

391 Long-term neurological symptoms significantly decrease the quality of life for
392 individuals, a situation that might be exacerbated by a pre-existing comorbidities[58].
393 Moreover, symptoms related to comorbidities often overlap with those of PCC, leading
394 individuals with obesity to attribute their symptoms to their metabolic disease rather than
395 to persistent manifestations of COVID-19[59, 60]. Additionally, overweight individuals
396 also report health complaints, including headache and sleeplessness, associated to their
397 subclinical disease state also known as suboptimal health status, which can be exacerbated
398 by PCC symptoms[20]. The co-occurrence of these complex conditions can have
399 deleterious effects, impairing people's daily functioning and increasing the demand on
400 healthcare systems. Our results highlight a significantly increased risk for persistent
401 headache, vertigo, numbness and taste disorder in individuals with EW or obesity. This
402 underscores the role of excessive body weight (fat deposits) in PCC. It is worth noting
403 that patients with PCC have reported that head pain worsens with physical exercise while
404 a decrease in physical activity coupled with increase in sedentary behaviour are generally
405 known to contribute to weight gain[61][62]. Moreover, taste disorders may influence
406 unhealthy weight-related behaviours, such as consuming more palatable, ultra-processed
407 foods high in salt, sugar, and additives. These foods can further impair gustatory function
408 and exacerbate unhealthy symptoms[63, 64]. Vertigo which impairs daily functioning by
409 increasing the risk of falls may also be associated with depression[65, 66]. Therefore,
410 healthcare systems and public policies should focus on multidisciplinary rehabilitation
411 services to address the long-term impacts of COVID-19 on survivors, specifically through
412 concomitant personalized management of weight, neurological and neuropsychiatric
413 issues.

414 The high prevalence of persistent complex concurrent symptoms may create a
415 vicious circle between physical and neuropsychiatric symptoms, increasing the risk for
416 depression[67–70]. A significant positive association between obesity and depressed
417 mood has been observed across multiple COVID-19 periods, similar to findings in other
418 coronavirus outbreaks[9, 14, 62]. During the COVID-19 pandemic, a systematic review
419 of longitudinal studies identified obesity/overweight as a risk factor for depression
420 (pooled RR = 1.2; 95% CI: 1.11-1.31). However, no significant association was found
421 when obesity/overweight was self-reported (pooled RR = 1.03; 95% CI: 0.99–1.26)[71].
422 In this study, we observed a heightened risk of persistent depression among individuals
423 with EW compared with those with normal weight. This findings aligns with Aminian *et*
424 *al.*[72] who reported that the need for diagnostic test to assess neuropsychiatric problems
425 (a *proxy* for symptoms) was significantly higher in individuals with increased BMI
426 compared to those with normal weight. Although our pooled RR for EW and depression
427 included data from two studies conducted with Asian populations[32, 40] featuring
428 different BMI assessments (measured and self-reported) and BMI cut-offs (excess weight
429 defined as BMI $\geq 23\text{kg/m}^2$ and obesity as BMI $\geq 25\text{kg/m}^2$), both studies used a validated
430 depression scale (PHQ-9), and the results were not heterogeneous.

431 It remains uncertain whether neurological and neuropsychiatric manifestations
432 related to PCC are directly attributable to the virus itself or if they develop indirectly
433 (such as, through an immune response or medical therapy). These symptoms may also
434 involve both the central and peripheral nervous systems[14]. Additionally, the role of EW
435 in the progression of COVID-19 is not fully understood, though it may be linked to an
436 exaggerated inflammatory response or shared pre-existing genetic factors that these
437 conditions share[73–75]. EW is also a recognized risk factor for various chronic
438 conditions and the number of pre-existing comorbidities has been associated to the

439 development of PCC symptoms up to two years after COVID-19 onset, in both
440 hospitalized and non-hospitalized patients[76]. Our results underscore the importance of
441 identifying at-risk individuals and highlight the need for timely personalized interventions
442 for COVID-19 survivors. These findings could inform the development of predictive and
443 preventive management plans for future waves of SARS-CoV-2 or other epidemics.

444 Our quality assessment results indicate that the included studies suffer from
445 methodological issues, particularly in measuring exposure. Studies that classified
446 individuals' nutritional status based on self-reported data were found to have a high risk
447 of bias, which contributed to downgrade in the overall quality of evidence of evaluated
448 for the evaluated symptoms. During the height of the pandemic, online health surveys
449 were often used when other research methods were infeasible[77]. However, significant
450 issues can also arise from self-reported symptoms in studies that did not employ
451 structured questionnaire or validated scales. Although screening tools have been proposed
452 to identify people with PCC they often do not consider neuropsychiatric symptoms[78]
453 or important cognitive symptoms[79] that significantly affect individuals' quality of life.
454 The observed moderate heterogeneity among studies evaluating headache, taste disorder
455 and vertigo has led to imprecision in the results and the limited number of studies included
456 in meta-analysis unable the assessment of publication bias, further contributing to
457 downgrade of the overall quality of evidence for those outcomes from high to very low.

458 It is important to acknowledge certain limitations when interpreting the findings
459 of our research. Most of the included studies were cross-sectional which limits the ability
460 to determine cause and effect relationships. The inconsistency in naming PCC symptoms
461 among studies resulted in a relatively low number of studies reporting the same symptom
462 which also precluded subgroup comparisons between hospitalized and outpatient
463 populations. We included studies that used non-validated questionnaires to assess

464 symptoms, as it was necessary given that PCC is an emerging condition and validated
465 screening tools have yet to be developed. Although the cut-off for study inclusion
466 regarding time to follow-up (i.e., >12 weeks) allowed us to track long-term outcomes
467 from COVID-19 and address a gap in the literature, the follow-up period ranged from 12
468 to 52 weeks post-infection, the varying risk of PCC symptoms throughout different
469 follow-up periods was not investigated in subgroup analysis due to limited number of
470 studies. Additionally, the inclusion of both obesity and non-obesity as comparisons
471 groups led to the interchange of overweight individuals between exposure and control
472 groups. Nevertheless, defining EW and obesity as exposure groups was crucial given the
473 syndemic context. This approach enabled the evaluation of the risk of developing
474 persistent symptoms among different levels of excessive fat and highlighted that both
475 suboptimal health status (overweight) and illness (obesity) predisposed individuals to
476 PCC-related neuro-symptoms. However, the inherent differences among these groups
477 should be considered in health, disease prevention and diagnoses. Furthermore, the issues
478 related to body fat assessment should be noted as BMI remains the most widely used
479 screening tool for measuring adiposity. Although it is a simple and non-invasive measure
480 often related to the gold standard fat assessment BMI does not accounts for the types or
481 distribution of adipose tissue, nor does it for age and ethnic backgrounds[80]. Future
482 research should focus on longitudinal evaluation of COVID-19 survivors incorporating
483 objective assessment of symptoms and adiposity.

484 Despite these limitations, our review has several scientific and clinical strengths.
485 Notably, the number of investigated outcomes allowed for a pioneering evaluation of the
486 association of EW with both the physical and psychological long-term manifestations of
487 COVID-19. Additionally, the comprehensive definition of PCC that we applied during
488 our article search (to account for varied terminology), along with the inclusion of each

489 neurological and neuropsychiatric symptom specified in our search strategy, ensured a
490 thorough screening process. We also underscored the importance of addressing EW as a
491 global health concern, given its interplay with neurological and neuropsychiatric
492 manifestations, and infectious diseases such as COVID-19. The management of EW
493 should be considered in the treatment of neurological and neuropsychiatric symptoms due
494 to the significant impact that these combined conditions have on individuals' health.

495

496 **Conclusions**

497 Our systematic review and meta-analysis demonstrate that EW is significantly
498 associated with an increased risk of developing post-COVID-19 neurological and
499 neuropsychiatric symptoms, including headache, memory issues, numbness, smell and
500 taste disorders, vertigo, depression, and sleep disturbance. These findings underscore the
501 need for developing multidisciplinary rehabilitative strategies tailored to individual needs
502 to improve care management and support the overall health of affected individuals. Our
503 results provide evidence-based guidance for healthcare professionals and policymakers
504 in managing PCC, and further support ongoing global efforts to understand its underlying
505 mechanisms, epidemiology, and identification.

506

507 **Acknowledgements:**

508 We would like to thank the researchers who shared information and enabled more precise
509 results in this study. We would also like to acknowledge students and collaborators of the
510 PENSA research group at the University of Brasília and the Centre for Precision Health
511 at Edith Cowan University for their support.

512

513 References

- 514 [1] Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19 — Implications for
515 the Health Care System. *N Engl J Med* 2020; 383: 1483–1488.
- 516 [2] Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al.
517 Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up
518 periods: a systematic review and meta-analysis. *Clin Microbiol Infect* 2022; 28:
519 657–666.
- 520 [3] Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.
521 Post-acute COVID-19 syndrome. *Nat Med* 2021; 27: 601–615.
- 522 [4] Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute
523 COVID-19. *JAMA* 2020; 324: 603–605.
- 524 [5] WHO. A clinical case definition of post-COVID-19 condition by a Delphi
525 consensus - The Lancet Infectious Diseases,
526 [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00703-](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00703-9/fulltext)
527 [9/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00703-9/fulltext) (accessed 15 October 2023).
- 528 [6] NICE NI for H and C of E. 1 Identification | COVID-19 rapid guideline: managing
529 the long-term effects of COVID-19 | Guidance | NICE,
530 <https://www.nice.org.uk/guidance/ng188/chapter/1-Identification> (2020, accessed
531 20 June 2024).
- 532 [7] Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-
533 acute covid-19 in primary care. *BMJ* 2020; 370: m3026.
- 534 [8] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings,
535 mechanisms and recommendations. *Nat Rev Microbiol* 2023; 21: 133–146.
- 536 [9] Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al.
537 Psychiatric and neuropsychiatric presentations associated with severe coronavirus
538 infections: a systematic review and meta-analysis with comparison to the COVID-
539 19 pandemic. *Lancet Psychiatry* 2020; 7: 611–627.
- 540 [10] Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute
541 sequelae of COVID-19. *Nature* 2021; 594: 259–264.
- 542 [11] Fanshawe JB, Sargent BF, Badenoch JB, Saini A, Watson CJ, Pokrovskaya A, et
543 al. Cognitive domains affected post-COVID-19; a systematic review and meta-
544 analysis. *Eur J Neurol*; n/a: e16181.
- 545 [12] Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD,
546 et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review
547 and meta-analysis. *Brain Commun* 2022; 4: fcab297.
- 548 [13] Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute
549 COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)—A
550 systematic review and meta-analysis. *J Med Virol* 2022; 94: 253–262.

- 551 [14] Pilotto A, Cristillo V, Cotti Piccinelli S, Zoppi N, Bonzi G, Sattin D, et al. Long-
552 term neurological manifestations of COVID-19: prevalence and predictive factors.
553 *Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol* 2021; 42: 4903–4907.
- 554 [15] Luo D, Mei B, Wang P, Li X, Chen X, Wei G, et al. Prevalence and risk factors for
555 persistent symptoms after COVID-19: a systematic review and meta-analysis. *Clin*
556 *Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 2024; 30: 328–335.
- 557 [16] Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et
558 al. Risk Factors Associated With Post–COVID-19 Condition: A Systematic
559 Review and Meta-analysis. *JAMA Intern Med* 2023; 183: 566–580.
- 560 [17] Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive
561 impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.
562 *Brain Behav Immun* 2022; 101: 93–135.
- 563 [18] Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al.
564 Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-
565 CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. *J*
566 *Clin Med* 2022; 11: 7314.
- 567 [19] Bray G a., Kim K k., Wilding J p. h., Federation on behalf of the WO. Obesity: a
568 chronic relapsing progressive disease process. A position statement of the World
569 Obesity Federation. *Obes Rev* 2017; 18: 715–723.
- 570 [20] Mahara G, Tan X, Wang W. Risk Factors, Health Status, and Risk Groups in
571 Suboptimal Health Condition. In: Wang W (ed) *All Around Suboptimal Health :
572 Advanced Approaches by Predictive, Preventive and Personalised Medicine for
573 Healthy Populations*. Cham: Springer Nature Switzerland, pp. 61–72.
- 574 [21] Hepatology TLG&. Obesity: another ongoing pandemic. *Lancet Gastroenterol*
575 *Hepatol* 2021; 6: 411.
- 576 [22] Lockhart SM, O’Rahilly S. When Two Pandemics Meet: Why Is Obesity
577 Associated with Increased COVID-19 Mortality? *Med N Y N* 2020; 1: 33–42.
- 578 [23] Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, et al. The
579 Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet
580 Commission report. *Lancet Lond Engl* 2019; 393: 791–846.
- 581 [24] Nagar M, Geevarughese NM, Mishra R, Joshi A, Galwankar S, Yunus M, et al.
582 Body-mass index COVID-19 severity: A systematic review of systematic reviews.
583 *J Fam Med Prim Care* 2022; 11: 5351–5360.
- 584 [25] Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients
585 with COVID-19: a systematic review and meta-analysis of observational studies.
586 *Anaesthesia* 2020; 75: 1340–1349.
- 587 [26] Chen Z, Peng Y, Wu X, Pang B, Yang F, Zheng W, et al. Comorbidities and
588 complications of COVID-19 associated with disease severity, progression, and
589 mortality in China with centralized isolation and hospitalization: A systematic
590 review and meta-analysis. *Front Public Health* 2022; 10: 923485.

- 591 [27] Staffolani S, Iencinella V, Cimatti M, Tavio M. Long COVID-19 syndrome as a
592 fourth phase of SARS-CoV-2 infection. *Infez Med* 2022; 30: 22–29.
- 593 [28] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
594 The PRISMA 2020 statement: an updated guideline for reporting systematic
595 reviews. *The BMJ* 2021; 372: n71.
- 596 [29] McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS
597 Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin
598 Epidemiol* 2016; 75: 40–46.
- 599 [30] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and
600 mobile app for systematic reviews. *Syst Rev* 2016; 5: 210.
- 601 [31] WHO Consultation on Obesity (1999: Geneva S, Organization WH. *Obesity :
602 preventing and managing the global epidemic : report of a WHO consultation.*
603 World Health Organization, <https://iris.who.int/handle/10665/42330> (2000,
604 accessed 12 June 2024).
- 605 [32] Li Z, He J, Wang Y, Bai M, Zhang Y, Chen H, et al. A cross-sectional study on the
606 mental health of patients with COVID-19 1 year after discharge in Huanggang,
607 China. *Eur Arch Psychiatry Clin Neurosci* 2023; 273: 301–310.
- 608 [33] Shang L, Wang L, Zhou F, Li J, Liu Y, Yang S. Long-term effects of obesity on
609 COVID-19 patients discharged from hospital. *Immun Inflamm Dis* 2021; 9: 1678–
610 1685.
- 611 [34] Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA, et al.
612 A tool to assess risk of bias in non-randomized follow-up studies of exposure
613 effects (ROBINS-E). *Environ Int* 2024; 186: 108602.
- 614 [35] Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers
615 and Communication Group,. *Cochrane. Consumers and Communication*,
616 <https://cccrg.cochrane.org/author-resources> (2016, accessed 8 November 2023).
- 617 [36] Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook,
618 <https://gdt.gradepro.org/app/handbook/handbook.html#h.h2a1ln3pqdrc> (accessed
619 18 June 2024).
- 620 [37] Guideline Development Tool,
621 [https://gdt.gradepro.org/app/#projects/p_1_deboraronca_gmail_com_0_1bcf9a94-
622 38f9-4870-ad7d-f19f0205fadc/evidence-syntheses/395b01fd-9923-48a0-81e7-
623 cf4c69f477d2/quality-of-evidence](https://gdt.gradepro.org/app/#projects/p_1_deboraronca_gmail_com_0_1bcf9a94-38f9-4870-ad7d-f19f0205fadc/evidence-syntheses/395b01fd-9923-48a0-81e7-cf4c69f477d2/quality-of-evidence) (accessed 18 June 2024).
- 624 [38] DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;
625 7: 177–188.
- 626 [39] Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane
627 Handbook for Systematic Reviews of Interventions,
628 <https://training.cochrane.org/handbook/current> (accessed 12 June 2024).

- 629 [40] Moy FM, Lim ERJ, Hairi NN, Bulgiba A. Depression and its associated factors
630 among COVID-19 survivors in a middle income country. 2022;
631 2022.12.15.22283550.
- 632 [41] Gaur R, Asthana S, Yadav R, Ghuleliya R, Kumar D, Akhtar M, et al. Assessment
633 of Physical Disability After Three Months in Patients Recovered From COVID-
634 19: A Cross-Sectional Study. *Cureus*; 14: e21618.
- 635 [42] Farhanah N, Charles Budiman, Muchlis Achsan Udji Sofro, Budi Riyanto, Suharyo
636 Hadisaputro, Muhammad Hussein Gasem. The Persistent Symptoms and
637 Decreased Quality of Life of COVID-19 Patients (A 3-month Follow-up after
638 Discharge) | Open Access Macedonian Journal of Medical Sciences,
639 <https://oamjms.eu/index.php/mjms/article/view/9755> (2024, accessed 9 June
640 2024).
- 641 [43] Miyazato Y, Tsuzuki S, Morioka S, Terada M, Kutsuna S, Saito S, et al. Factors
642 associated with development and persistence of post-COVID conditions: A cross-
643 sectional study. *J Infect Chemother* 2022; 28: 1242–1248.
- 644 [44] Alkwai HM, Khalifa AM, Ahmed AM, Alnajib AM, Alshammari KA, Alrashidi
645 MM, et al. Persistence of COVID-19 symptoms beyond 3 months and the delayed
646 return to the usual state of health in Saudi Arabia: A cross-sectional study. *SAGE*
647 *Open Med* 2022; 10: 20503121221129918.
- 648 [45] Sørensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. A
649 nationwide questionnaire study of post-acute symptoms and health problems after
650 SARS-CoV-2 infection in Denmark. *Nat Commun* 2022; 13: 4213.
- 651 [46] van Wijhe M, Fogh K, Ethelberg S, Karmark Iversen K, Nielsen H, Østergaard L,
652 et al. Persistent Symptoms and Sequelae After Severe Acute Respiratory Syndrome
653 Coronavirus 2 Infection Not Requiring Hospitalization: Results From Testing
654 Denmark, a Danish Cross-sectional Survey. *Open Forum Infect Dis* 2022; 10:
655 ofac679.
- 656 [47] Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al.
657 Persistent COVID-19 symptoms in a community study of 606,434 people in
658 England. *Nat Commun* 2022; 13: 1957.
- 659 [48] Bungenberg J, Humkamp K, Hohenfeld C, Rust MI, Ermis U, Dreher M, et al.
660 Long COVID-19: Objectifying most self-reported neurological symptoms. *Ann*
661 *Clin Transl Neurol* 2022; 9: 141–154.
- 662 [49] Vassalini P, Serra R, Tarsitani L, Koukopoulos AE, Borrazzo C, Alessi F, et al.
663 Depressive Symptoms among Individuals Hospitalized with COVID-19: Three-
664 Month Follow-Up. *Brain Sci* 2021; 11: 1175.
- 665 [50] Chudzik M, Lewek J, Kapusta J, Banach M, Jankowski P, Bielecka-Dabrowa A.
666 Predictors of Long COVID in Patients without Comorbidities: Data from the Polish
667 Long-COVID Cardiovascular (PoLoCOV-CVD) Study. *J Clin Med* 2022; 11:
668 4980.

- 669 [51] Fernández-de-las-Peñas C, Torres-Macho J, Elvira-Martínez CM,
670 Molina-Trigueros LJ, Sebastián-Viana T, Hernández-Barrera V. Obesity is
671 associated with a greater number of long-term post-COVID symptoms and poor
672 sleep quality: A multicentre case-control study. *Int J Clin Pract* 2021; 75: e14917.
- 673 [52] Desgranges F, Tadini E, Munting A, Regina J, Filippidis P, Viala B, et al.
674 Post-COVID-19 Syndrome in Outpatients: a Cohort Study. *J Gen Intern Med* 2022;
675 37: 1943–1952.
- 676 [53] Blümel JE, Vallejo MS, Bencosme A, Calle A, Dextre M, Díaz K, et al. Post-
677 COVID-19 syndrome in a sample of climacteric women living in Latin America.
678 *Menopause N Y N* 2023; 30: 165–173.
- 679 [54] Carter SJ, Baranauskas MN, Raglin JS, Pescosolido BA, Perry BL. Functional
680 Status, Mood State, and Physical Activity Among Women With Post-Acute
681 COVID-19 Syndrome. *Int J Public Health* 2022; 67: 1604589.
- 682 [55] Epsi NJ, Chenoweth JG, Blair PW, Lindholm DA, Ganesan A, Lalani T, et al.
683 Precision Symptom Phenotyping Identifies Early Clinical and Proteomic
684 Predictors of Distinct COVID-19 Sequelae. *J Infect Dis* 2024; jiae318.
- 685 [56] Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati
686 C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. Estimated Global Proportions of
687 Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters
688 Following Symptomatic COVID-19 in 2020 and 2021. *JAMA* 2022; 328: 1604–
689 1615.
- 690 [57] Lledó GM, Sellares J, Brotons C, Sans M, Antón JD, Blanco J, et al. Post-acute
691 COVID-19 syndrome: a new tsunami requiring a universal case definition. *Clin
692 Microbiol Infect* 2022; 28: 315–318.
- 693 [58] Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive
694 dysfunction: current status and research recommendations for high risk population.
695 *Lancet Reg Health – West Pac*; 38. Epub ahead of print 1 September 2023. DOI:
696 10.1016/j.lanwpc.2023.100836.
- 697 [59] Mansell V, Dykgraaf SH, Kidd M, Goodyear-Smith F. Long COVID and older
698 people. *Lancet Healthy Longev* 2022; 3: e849–e854.
- 699 [60] Wilk P, Stranges S, Cuschieri S. Does sex modify the effect of pre-pandemic body
700 mass index on the risk of Long COVID? Evidence from the longitudinal analysis
701 of the Survey of Health, Ageing and Retirement in Europe. *Int J Obes* 2024;
702 48: 821–829.
- 703 [61] Tana C, Giamberardino MA, Martelletti P. Long COVID and especially headache
704 syndromes. *Curr Opin Neurol* 2023; 36: 168.
- 705 [62] Melamed OC, Selby P, Taylor VH. Mental Health and Obesity During the COVID-
706 19 Pandemic. *Curr Obes Rep* 2022; 11: 23–31.

- 707 [63] Avila C, Holloway AC, Hahn MK, Morrison KM, Restivo M, Anglin R, et al. An
708 Overview of Links Between Obesity and Mental Health. *Curr Obes Rep* 2015; 4:
709 303–310.
- 710 [64] Contreras-Rodriguez O, Solanas M, Escorihuela RM. Dissecting ultra-processed
711 foods and drinks: Do they have a potential to impact the brain? *Rev Endocr Metab*
712 *Disord* 2022; 23: 697–717.
- 713 [65] Gunes-Bayir A, Tandogan Z, Gedik-Toker Ö, Yabaci-Tak A, Dadak A. A
714 Comparison Study of Nutritional Assessment, Diet and Physical Activity Habits,
715 Lifestyle and Socio-Demographic Characteristics in Individuals with and without
716 Dizziness/Vertigo. *Nutrients* 2023; 15: 4055.
- 717 [66] Neuhauser HK. The epidemiology of dizziness and vertigo. *Handb Clin Neurol*
718 2016; 137: 67–82.
- 719 [67] Hassan NM, Salim HS, Amaran S, Yunus NI, Yusof NA, Daud N, et al. Prevalence
720 of mental health problems among children with long COVID: A systematic review
721 and meta-analysis. *PLOS ONE* 2023; 18: e0282538.
- 722 [68] Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term
723 effects of COVID-19 on mental health: A systematic review. *J Affect Disord* 2022;
724 299: 118–125.
- 725 [69] Staples LG, Nielssen O, Dear BF, Bisby MA, Fisher A, Kayrouz R, et al.
726 Prevalence and Predictors of Long COVID in Patients Accessing a National Digital
727 Mental Health Service. *Int J Environ Res Public Health* 2023; 20: 6756.
- 728 [70] van der Feltz-Cornelis C, Turk F, Sweetman J, Khunti K, Gabbay M, Shepherd J,
729 et al. Prevalence of mental health conditions and brain fog in people with long
730 COVID: A systematic review and meta-analysis. *Gen Hosp Psychiatry* 2024; 88:
731 10–22.
- 732 [71] Amiri S, Behnezhad S, Nadinlui KB. Body Mass Index (BMI) and risk of
733 depression in adults: A systematic review and meta-analysis of longitudinal
734 studies. *Obes Med* 2018; 12: 1–12.
- 735 [72] Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with
736 postacute sequelae of COVID-19. *Diabetes Obes Metab* 2021; 23: 2183–2188.
- 737 [73] N S, Ib M, Jjv M. Obesity Is a Risk Factor for Severe COVID-19 Infection:
738 Multiple Potential Mechanisms. *Circulation*; 142. Epub ahead of print 7 July 2020.
739 DOI: 10.1161/CIRCULATIONAHA.120.047659.
- 740 [74] McNeill JN, Lau ES, Paniagua SM, Liu EE, Wang JK, Bassett IV, et al. The role
741 of obesity in inflammatory markers in COVID-19 patients. *Obes Res Clin Pract*
742 2021; 15: 96–99.
- 743 [75] N A, My K, Pb M, Se P. Causal Inference for Genetic Obesity, Cardiometabolic
744 Profile and COVID-19 Susceptibility: A Mendelian Randomization Study. *Front*
745 *Genet*; 11. Epub ahead of print 11 November 2020. DOI:
746 10.3389/fgene.2020.586308.

- 747 [76] Fernández-de-las-Peñas C, Rodríguez-Jiménez J, Cancela-Cilleruelo I, Guerrero-
748 Peral A, Martín-Guerrero JD, García-Azorín D, et al. Post–COVID-19 Symptoms
749 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized
750 Patients. *JAMA Netw Open* 2022; 5: e2242106.
- 751 [77] Hlatshwako TG, Shah SJ, Kosana P, Adebayo E, Hendriks J, Larsson EC, et al.
752 Online health survey research during COVID-19. *Lancet Digit Health* 2021; 3:
753 e76–e77.
- 754 [78] Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al.
755 Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.
756 *JAMA* 2023; 329: 1934–1946.
- 757 [79] Burns G. Newcastle Post-COVID Syndrome Follow Up Screening Questionnaire,
758 [https://postcovidsyndromebsol.nhs.uk/images/Content/
759 Newcastle_post_Covid_Screening_Tool.pdf](https://postcovidsyndromebsol.nhs.uk/images/Content/Newcastle_post_Covid_Screening_Tool.pdf). (accessed 12 July 2024).
- 760 [80] Zhang X, Ha S, Lau HC-H, Yu J. Excess body weight: Novel insights into its roles
761 in obesity comorbidities. *Semin Cancer Biol* 2023; 92: 16–27.
- 762

764 **Supporting Information**

765

766 **S1 Table. Database search strategy.**

767 **S2 Table. Frequency of Post-COVID Condition neuropsychiatric symptoms of**
768 **included studies that did not test for statistical differences according to nutritional**

769 **status.** Excess weight group (BMI \geq 25kg/m²); NW: Normal Weight group (BMI < 25kg/m²); Obesity
770 group (BMI \geq 30kg/m²); NOb: Non-obesity group (BMI < 30kg/m²).

771 **S1 Fig 1a: Forest-plots of excess weight and neuropsychiatric symptoms (non-**
772 **significantly associations).**


773 **S1 Fig 1b. Forest-plots of obesity and neurological and neuropsychiatric symptoms**
774 **(non-significantly associations)**

775 **S2 Fig 2. Forest-plot of the association of excess weight and the risk of neurological**
776 **and neuropsychiatric symptoms.**

777 **S3 Fig 3. Traffic light plots of risk of bias of included studies that reported the risk**
778 **of developing neuro-symptoms assessed by Robbins-e tool.**


779 **S3 Table 3. Assessment of the overall certainty of the evidence for studies thar**
780 **compared the frequency of PCC neurological and neuropsychiatric symptoms**
781 **among individuals with obesity and control groups**

(a) Depression



Random-effects DerSimonian-Laird model

(b) Sleep disturbance



Random-effects REML model

(c) Headache






Figure 3a

(d) Memory issues




Random-effects DerSimonian-Laird model

(e) Numbness




Random-effects DerSimonian-Laird model

(f) Taste disorder




Random-effects DerSimonian-Laird model

(g) Vertigo




Random-effects DerSimonian-Laird model


Figure 3b

(a) Headache

Random-effects REML model

(b) Memory issues


Random-effects DerSimonian-Laird model

(c) Numbness

Random-effects DerSimonian-Laird model


Figure 4a

(d) Smell disorder




Random-effects DerSimonian-Laird model

(e) Taste disorder



Random-effects DerSimonian-Laird model

(f) Vertigo



Random-effects DerSimonian-Laird model

Figure 4b




Figure 5




Figure 1




Figure 2